All In Biotech

BLA 125117 · Biomarin

Naglazyme

Galsulfase · Injection · Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

May 31, 2005

Approved uses

4

Original approval plus efficacy supplements

Registered trials

3

0 Phase 3, 1 recruiting

FAERS reports

3,877

2,558 serious, 352 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate NAGLAZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue NAGLAZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING...

What it is approved for

From the label in effect Sep 18, 2024.

NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity. NAGLAZYME is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity. ( 1 )

Mechanism: Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of GAG. MPS VI is characterized by the absence or marked reduction in N-acetylgalactosamine 4-sulfatase. The sulfatase activity deficiency results in the accumulation of the GAG substrate, dermatan sulfate, throughout the body. This accumulation leads to widespread cellular, tissue, and organ dysfunction. NAGLAZYME is intended to provide an exogenous enzyme that will be taken up into lysosomes and increase the catabolism of GAG. Galsulfase uptake by cells into lysosomes...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 28, 2011 Supplement 88 · Efficacy OrphanLabelLetter
  • Apr 28, 2011 Supplement 86 · Efficacy LabelLetter
  • Apr 28, 2011 Supplement 90 · Efficacy OrphanLabelLetter
  • May 31, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
  • NAGLAZYME · GALSULFASE 5MG/5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Galsulfase" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia420
  • pneumonia307
  • cough228
  • dyspnoea195
  • spinal cord compression161
  • vomiting133
  • oxygen saturation decreased131
  • fatigue113
  • headache95
  • pain92
  • influenza91
  • death90

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
200819
200938
201068
2011113
2012126
2013113
2014483
2015335
2016224
2017233
2018239
2019255
2020250
2021266
2022289
2023213
2024224
2025240
2026148

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Naglazyme (Galsulfase)

2024 spending

$5.1M

Beneficiaries

n/a

42 claims

Per beneficiary

n/a

$447.58 per unit

View as table
YearSpending
2020$8,109,419
2021$6,204,188
2022$5,999,848
2023$6,148,670
2024$5,075,599

Part B: Naglazyme (Galsulfase) · HCPCS J1458

2024 spending

$393K

Beneficiaries

n/a

23 claims

Per beneficiary

n/a

2024 ASP limit $472.58 per unit

View as table
YearSpending
2020$746,056
2021$445,531
2022$0
2023$0
2024$393,377

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: BioMarin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.